2018 International Congress » Huntington's Disease

Date: Sunday, October 7, 2018

Time: 1:45pm-3:15pm

Location: Hall 3FG

Meeting: 2018 International Congress

1:45pm-3:15pm: A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)

M. Delnomdedieu, Y. Tan, A. Ogde, Z. Berger, R. Reilmann (Cambridge, MA, USA)

1:45pm-3:15pm: A Study on Combined Brain Positron Emission Tomography (PET) – Magnetic Resonance Imaging (MRI) Using Fluorodeoxyglucose (18FDG) (FDG-PET/MRI) in Premanifest Huntington’s Disease Gene-expansion Carriers

M. Hellem, T. Vinther-Jensen, C. Hansen, E. Budtz-Jørgensen, L. Hjermind, I. Law, J. Nielsen (Copenhagen, Denmark)

1:45pm-3:15pm: Assessing the potential of EEG as a biomarker in Huntington’s disease using machine learning automatic classification

O. Odish, K. Johnsen, P. van Someren, R. Roos, G. van Dijk (Leiden, Netherlands)

1:45pm-3:15pm: Cerebrospinal fluid flow dynamics in Huntington’s disease evaluated by phase contrast MRI

F. Rodrigues, L. Byrne, E. De Vita, E. Johnson, N. Hobbs, J. Thornton, R. Scahill, E. Wild (London, United Kingdom)

1:45pm-3:15pm: Cerebrospinal fluid proteomics reveals alterations of the renin-angiotensin system in Huntington’s disease

V. Niemelä, J. Sundblom, A.M. Landtblom, D. Nyholm (Uppsala, Sweden)

1:45pm-3:15pm: Clinical and genetic data of Huntington disease in Uzbekistan patient

M. Rakhimova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Cognitive Reserve and Physical Activity Modulate Functional Brain Re-organisation in Premanifest Huntington’s Disease: Preliminary Evidence

M. Soloveva, S. Jamadar, G. Poudel, N. Georgiou-Karistianis (Melbourne, Australia)

1:45pm-3:15pm: Comparing risperidone and olanzapine to tetrabenazine for the management of Huntington’s chorea

J. Schultz, J. Kamholz, P. Nopoulos, A. Killoran (Iowa City, IA, USA)

1:45pm-3:15pm: Decision making in Huntington’s disease

B. Heim, M. Peball, P. Ellmerer, C. Saft, S.M. von Hein, W. Poewe, K. Seppi, A. Djamshidian (Innsbruck, Austria)

1:45pm-3:15pm: Driving performance of Huntington’s disease gene carriers

M. Jacobs, E. Hart, Y. Mejia Miranda, G.J. Groeneveld, J. van Gerven, R. Roos (Leiden, Netherlands)

1:45pm-3:15pm: Elevated serum α-synuclein levels in Huntington’s disease patients

M. Breza, E. Emmanouilidou, G. Karadima, C.H. Kartanou, M. Panas, K. Vekrellis, G. Koutsis (Athens, Greece)

1:45pm-3:15pm: Evaluation of motor impulsivity in Huntington Disease with a choice reaction time task and brain metabolic (PET 18FDG) imaging

S. Grimaldi, E. Guedj, F. Fluchere, T. Hasbroucq, F. Vidal, JP. Azulay (Marseille, France)

1:45pm-3:15pm: Exploration of insight competence in Huntington’s disease supplemental to a cognitive debriefing study for the FuRST2.0 rating scale

R. Fuller, P. Feigenbaum, C. Fitzer-Attas, N. La Pelle, S. Luo, C. Sampaio, G. Stebbins (Princeton, NJ, USA)

1:45pm-3:15pm: Huntington disease like 2 in South Africa

M. Khider, K. Naidu, J. Carr (Cape Town, South Africa)

1:45pm-3:15pm: Interrater reliability of the Unified Huntington’s Disease Rating Scale-Total Motor Score certification

J. Winder, R. Roos, J.M. Burgunder, J. Marinus, R. Reilmann (Leiden, Netherlands)

1:45pm-3:15pm: Investigating the clinical predictors of depression in Huntington’s disease: An Enroll-HD Database Study

E. Furr Stimming, G. Colpo, N. Rocha, A. Teixeira (Houston, TX, USA)

1:45pm-3:15pm: Late onset Huntington’s disease in an Argentinian cohort

M. Cesarini, J. Etcheverry, E. Gatto, J. Ziliani, G. Da Prat, N. Gonzalez Rojas, V. Parisi, G. Persi (Buenos Aires, Argentina)

1:45pm-3:15pm: Malignant gliomas in patients with Huntington’s disease

S. Chandra, G. Suarez-Cedeno, E. Stimming (Houston, TX, USA)

1:45pm-3:15pm: Neurofilament light protein: An emerging clinical and translational biofluid biomarker for Huntington’s disease

L. Byrne, F. Rodrigues, E. Johnson, S. Gregory, R. Soylu Kucharz, M. Björkqvist, A. Heslegrave, K. Blennow, A. Durr, B. Leavitt, R. Roos, S. Tabrizi, H. Zetterberg, D. Langbehn, R. Scahill, E. Wild (London, United Kingdom)

1:45pm-3:15pm: Neuronal correlates of oculomotor alterations in Huntington’s disease. A 18-FDG PET study

J. Perez, S. Martinez Horta, F. Sampedro, J. Pagonabarraga, A. Horta, D. Lopez Mora, A. Lozano, V. Camacho, B. Gomez-Anson, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

P. Kashyap, S. Gupta (Bihar, India)

1:45pm-3:15pm: On the hunt for a link between genetically confirmed Huntington’s disease and Amyotrophic Lateral Sclerosis

L. Williams, K. O'Connell, D. Burke, J. Cryan, D. McCabe (Dublin, Ireland)

1:45pm-3:15pm: Parallel evaluation of mutant huntingtin and neurofilament light in Huntington’s disease

L. Byrne, F. Rodrigues, E. Johnson, E. De Vita, C. Czech, S. Schobel, R. Scahill, A. Heslegrave, H. Zetterberg, W. Wild (London, United Kingdom)

1:45pm-3:15pm: Pharmacological investigation of biochemical and behavioral effects resembling Huntington’s disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor

R. Mishra (Baddi, India)

1:45pm-3:15pm: Prediction of suicidality in Huntington disease: Analysis of Enroll-HD data using machine learning approach

Y. Seliverstov, A. Borzov, E. van Duijn, B. Landwehrmeyer, M. Belyaev (Moscow, Russian Federation)

1:45pm-3:15pm: Prevalence of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease

S. Hung, D. Claassen, M. Edmondson, R. Reilmann, N. Svrzikapa, K. Longo, J. Goyal, M. Panzara (Cambridge, MA, USA)

1:45pm-3:15pm: Speech in Huntington’s Disease

J.C.S. Chan, A. Vogel, J. Stout (Victoria, Australia)

1:45pm-3:15pm: The distinct cognitive syndromes of Huntington’s disease: A two-year follow-up study

S. Martinez-Horta, F. Sampedro, A. Horta-Barba, J. Perez-Perez, J. Pagonabarraga, J. Marin-Lahoz, H. Bejr-Kasem, I. Aracil, MA. Boti, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: The impact of bilingualism in brain structure and function in early and mild Huntington’s disease

S. Martinez-Horta, A. Moreu, F. Sampedro, J. Perez-Perez, A. Horta-Barba, J. Pagonabarraga, J. Marin-Lahoz, H. Bejr-Kasem, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Treating Huntington’s Disease using a holistic approach

T. Sinha (Patna, India)

1:45pm-3:15pm: Vertical and horizontal eye movements in a large cohort of early manifest Huntington’s disease: Evidence from ENROLL-HD

W. Muller, M. MacAskill, L. Paermentier, T. Anderson (Christchurch, New Zealand)

1:45pm-3:15pm: White matter microstructural alterations in Huntington Disease: When neurodegeneration starts?

P. Azevedo, L. Piovesana, M. Nogueira, R. Guimarães, A. Amato Filho, F. Cendes, Í. Lopes-Cendes, C. Yasuda (Campinas, Brazil)

« View all sessions from the 2018 International Congress.